secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0001493152-24-032831
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics receives NYSE delisting notice for equity shortfall; ONP-002 Phase 2 trial planned Q4 2024
--------------------------------------------------------------------------------

- NYSE American notified Oragenics it is not in compliance with Section 1003(a)(i) (stockholders' equity <$2M); compliance plan approved, deadline Oct 18, 2025.
- ONP-002 cleared FDA-required cardiotoxicity and genotoxicity tests; Phase 2 trial expected to start Q4 2024 in Australia.
- Improved intranasal formulation increases ONP-002 per dose by 4X; automated device prototype for use in acute concussion completed.
- Closed public offering raising ~$1.1M to fund ONP-002 development and corporate needs.
- Appointed Dr. Peacock as Chief Clinical Officer and Dr. Kelly as Chief Medical Officer for Phase 2 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224032831/0001493152-24-032831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224032831/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer